Linking Biochemical, Pathologic, and Clinical Events in Acute Coronary Syndromes

  • Richard C. Becker
Part of the Contemporary Cardiology book series (CONCARD)


Acute coronary syndromes represent the ultimate clinical expression of biochemical events and pathological processes occurring within atherosclerotic plaques. The sudden or rapidly progressive transition from a stable to an unstable clinical state implies increasing activity within the atheromatous core. Indeed, patients with unstable angina, non-ST-segment elevation myocardial infarction (MI), and ST-segment elevation MI are all at the metamorphosis stage of their disease. Much like physiologic hemostasis, pathologic thrombosis, representing the final common event that links acute coronary syndromes, represents a response to localized vascular injury and inflammation; however, unlike normal hemostasis, the cascade of events that follows is poorly regulated and responsible for compromised myocardial perfusion and at times cellular death.


Acute Coronary Syndrome Atherosclerotic Plaque Unstable Angina Tissue Factor Plasminogen Activator Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Furchgott RF, Zawadski JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle cells by acetycholine. Nature 1980; 288: 373–376.PubMedGoogle Scholar
  2. 2.
    Marcum JA, Rosenberg RD. Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun 1985; 126: 365–372.PubMedGoogle Scholar
  3. 3.
    Vogel KG, Peterson DW. Extracellular, surface and intracellular proteglycans produced by human embryo lung fibroblasts in culture. J Biol Chem 1981; 256: 13235–13240.PubMedGoogle Scholar
  4. 4.
    Jarvelainen HT, Kinsella MG, Wight TN, Sandell LJ. Differential expression of small chondroitin/ dermatan sulfate proteoglycans, PG-I/biglycan and PG-II/decorin, by vascular smooth muscle and endothelial cells in culture. J Biol Chem 1991; 266: 23274–23279.PubMedGoogle Scholar
  5. 5.
    Kresse H, Hausser H, Schonherr E, Bittner K. Biosynthesis and interactions of small chondroitin/ dermatan sulfate proteoglycans. Eur J Clin Chem Clin Biochem 1994; 32: 259–266.PubMedGoogle Scholar
  6. 6.
    Heeb MJ, Mesters RM, Tans G, Rosing J, Griffin JH. Binding of protein S to factor Va associated with inhibition of prothrombinase that is independent of activated protein C. J Biol Chem 1993; 268: 2872–2877.PubMedGoogle Scholar
  7. 7.
    Broze GJ Jr, Warren LA, Novotny WF, Higuchi DA, Girard TJ, Miletich JP. The lipoprotein-associated coagulation inhibitor that inhibits factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood 1988; 71: 335–343.PubMedGoogle Scholar
  8. 8.
    van’t Veer C, Hackeng TM, Delahaye C, Sixma JJ, Bouma BN. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. Blood 1994; 84: 1132–1139.Google Scholar
  9. 9.
    Kaiser B, Hoppensteadt DA, Jeske W, Wun TC, Fareed J. Inhibitory effects of TFPI of thrombin and factor Xa generation in vitro-modulatory action of glycosaminoglycans. Thromb Res 1994; 75: 609–619.PubMedGoogle Scholar
  10. 10.
    Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 3353–3357.PubMedGoogle Scholar
  11. 11.
    Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, Kisiel W. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 1996; 35: 266–272.PubMedGoogle Scholar
  12. 12.
    Tait JF, Gibson D, Fujikawa K. Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family J Biol Chem 1989; 264: 7944–7951.Google Scholar
  13. 13.
    Yamamoto H, Bossaller C, Cartwright J Jr, Henry PD. Videomicroscopic demonstration of defective cholinergic arteriolar vasodilation in atherosclerotic rabbit. J Clin Invest 1988; 81: 1752–1758.PubMedGoogle Scholar
  14. 14.
    Sellke FW, Armstrong ML, Harrison DG. Endothelium-dependent vascular relaxation is abnormal in the coronary microcirculation of atherosclerotic primates. Circulation 1990; 81: 1585–1593.Google Scholar
  15. 15.
    Zeiher AM, Drexler H, Wollschlager H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984–1992.PubMedGoogle Scholar
  16. 16.
    Stern DM, Drillings M, Nossel HL, Harlet-Jensen A, LaGamma KS, Owen J. Binding of factors IX and Ixa to cultured endothelial cells. Proc Natl Acad Sci USA 1983; 80: 4119–4123.PubMedGoogle Scholar
  17. 17.
    Stern DM, Nawroth PP, Kisiel W, Vehar G, Esmon CT. The binding of factor Ixa to cultured bovine aortic endothelial cells. J Biol Chem 1985; 260: 6717–6722.PubMedGoogle Scholar
  18. 18.
    Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, et al. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 71: 1893–1896.PubMedGoogle Scholar
  19. 19.
    Yang Z, Arnet U, Bauer E, von Segesser L, Siebenmann R, Turina M, et al. Thrombin-induced endothelium-dependent inhibition and direct activation of platelet-vessel wall interaction: role of prostacyclin, nitric oxide, ancd thromboxane A2. Circulation 1994; 86: 2266–2272.Google Scholar
  20. 20.
    Caplan BA, Gerrity RG, Schwartz CJ. Endothelial cell morphology in focal areas of in vivo Evans Blue uptake in the young pig aorta. I. Quantitative light microscopic findings. Exp Mol Pathol 1974; 21: 102–117.PubMedGoogle Scholar
  21. 21.
    Jauchem JR, Lopez M, Sprague EA, Schwartz CJ. Mononuclear cell chemoattractant activity from cultured arterial smooth muscle cells. Exp Mol Pathol 1982; 37: 166–174.PubMedGoogle Scholar
  22. 22.
    Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Suenram CA, Rozek MM. Atherosclerosis as an inflammatory process: the roles of the monocyte-macrophage. Ann NY Acad Sci 1985; 454: 115–120.PubMedGoogle Scholar
  23. 23.
    Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Suenram CA, Graves DT, et al. Monocyte-macrophage participation in atherogenesis: inflammatory components of pathogenesis. Semin Thromb Hemost 1986; 12: 79–86.PubMedGoogle Scholar
  24. 24.
    Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci USA 1979; 76: 333–337.PubMedGoogle Scholar
  25. 25.
    Brown MS, Basu SK, Falck JR, Ho YK, Goldstein JL. The scavenger cell pathway for lipoprotein degradation: specificity of the binding site that mediates the uptake of negatively charged LDL by macrophages. J Supramol Str 1980; 13: 67–81.Google Scholar
  26. 26.
    Khoo JC, Miller E, McLoughlin P, Steinberg D. Enhanced macrophage uptake of low density lipoprotein after self-aggregation. Arteriosclerosis 1988; 8: 348–358.PubMedGoogle Scholar
  27. 27.
    Frank JS, Fogelman AM. Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching. J Lipid Res 1989; 30: 34967–34978.Google Scholar
  28. 28.
    Guyton JR, Klemp KF, Mims MP. Altered ultrastructural morphology of self-aggregated low density lipoproteins: coalescence of lipid domains forming droplets and vesicles. J Lipid Res 1991; 32: 953–962.PubMedGoogle Scholar
  29. 29.
    Lovanen PT, Kokkonen JO. Modification of low density lipoproteins by secretory granules of rat serosal mast cells. J Biol Chem 1991; 266: 4430–4436.Google Scholar
  30. 30.
    Steinbrecher UP, Lougheed M. Scavenger receptor-independent stimulation of cholesterol esterification in macrophages by low density lipoproteins extracted from human aortic intima. Arteroscler Thromb 1992; 12: 608–625.Google Scholar
  31. 31.
    Xu XX, Tabas I. Sphingomyelinase enhances low density lipopotein uptake and ability to induce cholesterl ester accumulation in macrophages. J Biol Chem 1991; 226: 24849–24858.Google Scholar
  32. 32.
    Tirzui D, Bobrian A, Tasca C, Simionescu M, Simionescu N. Intimal thickenings of human aorta contain modified reassembled lipoproteins. Atherosclerosis 1995; 112: 101–114.Google Scholar
  33. 33.
    Hollander W, Colombo MA, Kirkpatrick B, Paddock J. Soluble proteins in the human atherosclerotic plague: with special reference to immunoglobulins, C3-complement component, alpha I-antitrypsin and alpha 2-macroglobulin. Atherosclerosis 1979; 34: 391–405.PubMedGoogle Scholar
  34. 34.
    Rus HG, Niculescu F, Constantinescu E, Cristea A, Vlaicu R. Immunoelectron-microscopic localization of the terminal C5b-9 complement complex in human atherosclerotic fibrous plaque. Atherosclerosis 1986; 61: 35–42.PubMedGoogle Scholar
  35. 35.
    Reynolds GD, Vance RP. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Arch Pathol Lab Med 1987; 111: 265–269.PubMedGoogle Scholar
  36. 36.
    Hoff HF, Heideman CL, Gaubatz JW, Scott DW, Titus JL, Gotto AM Jr. Correlation of apolipoprotein B retention with the structure of atherosclerotic plaques from human aortas. Lab Invest 1978; 38: 560–567.PubMedGoogle Scholar
  37. 37.
    Hansson GK, Seifert PS. Complement receptors and regulatory proteins in human atherosclerotic lesions. Arteriosclerosis 1989; 9: 802–811.PubMedGoogle Scholar
  38. 38.
    Seifert PS, Hugo F, Hansson GK, Bhakdi S. Prelesional complement activation in experimental atherosclerosis. Lab Invest 1989; 60: 747–754.PubMedGoogle Scholar
  39. 39.
    Little WC, Constantinescu M, Applegate RJ, Kutcher MA, Burrows MT, Kahl FR, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 1988; 78: 1157–1166.PubMedGoogle Scholar
  40. 40.
    Davies MJ, Thomas AC. Plaque fissuring-the cause of acute myocardial infarction, sudden ischemic death and crescendo angina. Br Heart J 1985; 53: 363–373.PubMedGoogle Scholar
  41. 41.
    Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377–381.PubMedGoogle Scholar
  42. 42.
    Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: implications for plaque rupture. Circulation 1994; 90: 775–778.PubMedGoogle Scholar
  43. 43.
    Galis Z, Sukhova G, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995; 92: 402–406.PubMedGoogle Scholar
  44. 44.
    Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125–2131.PubMedGoogle Scholar
  45. 45.
    Amento EP, Ehsani N, Palmer H, Libby P. Cytokines positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb 1991; 11: 1223–1230.PubMedGoogle Scholar
  46. 46.
    Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169–175.PubMedGoogle Scholar
  47. 47.
    Kaartinen M, Penttila A, Kovanen PT. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 1994; 90: 1669–1678.PubMedGoogle Scholar
  48. 48.
    Constantinides P Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 1995; 92: 1084–1088.Google Scholar
  49. 49.
    Enos WF, Holmes RH, Beyer J. Coronary disease among United States soldiers killed in action in Korea. JAMA 1953; 152: 1090.Google Scholar
  50. 50.
    Davies PF, Remuzzi A, Gordon EJ, Dewey CF Jr, Gimbrone MA Jr. Turbulent fluid shear stress induces vascular endothelial cell turnover in vitro. Proc Natl Acad Sci USA 1986; 83: 2114–2117.PubMedGoogle Scholar
  51. 51.
    Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989; 2: 941–944.PubMedGoogle Scholar
  52. 52.
    Loree HM, Kamm RD, Stringfellow RG, Lee RT. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 1992; 71: 850–858.PubMedGoogle Scholar
  53. 53.
    Lee RT, Grodzinsky AJ, Frank EH, Kamm RD, Schoen FJ. Structure dependent dynamic mechanical behavior of fibrous caps from human atherosclerotic plaques. Circulation 1991; 83: 1764–1770.PubMedGoogle Scholar
  54. 54.
    Tofler GH, Stone PH, Maclure M, Edelman E, Davis VG, Robertson T, et al. Analysis of possible triggers of acute myocardial infarction (The MILIS Study). Am J Cardiol 1990; 66: 22–27.PubMedGoogle Scholar
  55. 55.
    Sumiyoshi T. Evaluation of clinical factors involved in onset of myocardial infarction. Jpn Circ J 1986; 50: 164–173.PubMedGoogle Scholar
  56. 56.
    Behar S, Halabi M, Reicher-Reiss H, Zion M, Kaplinsky E, Mandelzweig L, et al. Circadian variation and possible external triggers of onset of myocardial infarction. Am J Med 1993; 94: 395–400.PubMedGoogle Scholar
  57. 57.
    Tofler GH, Muller JE, Stone PH, Forman S, Solomon RE, Knatterud GL, Braunwald E. Modifiers of timing and possible triggers of acute myocardial infarction in the TIMI II population. J Am Coll Cardiol 1992; 20: 1049–1055.PubMedGoogle Scholar
  58. 58.
    Mittleman MA, Maclure M, Tofler GH, Sherwood JB, Goldberg RJ, Muller JE. Triggering of acute myocardial infarction by heavy exertion: protection against triggering by regular exertion. N Engl J Med 1993; 329: 1677–1683.PubMedGoogle Scholar
  59. 59.
    Willich SN, Lewis M, Lowel H, Arntz HR, Schubert F, Schroder R. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med 1993; 329: 1684–1690.PubMedGoogle Scholar
  60. 60.
    Winther K, Hillegass W, Tofler GH, Jimenez A, Brezinski DA, Schafer AI, et al. Effects on platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men. Am J Cardiol 1992; 70: 1051–1055.PubMedGoogle Scholar
  61. 61.
    Williams RB. Psychological factors in coronary artery disease: epidemiological evidence. Circulation 1987;76(Suppl I):I-117-I-123.Google Scholar
  62. 62.
    Jern C, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jern S. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Hemost 1989; 62: 767–771.Google Scholar
  63. 63.
    Yusuf S, Peto J, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–371.PubMedGoogle Scholar
  64. 64.
    The SOLVD Investigators. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691.Google Scholar
  65. 65.
    Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562–1569.PubMedGoogle Scholar
  66. 66.
    Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276–1282.PubMedGoogle Scholar
  67. 67.
    Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA 1912; 59: 2015–2020.Google Scholar
  68. 68.
    Saphir O, Priest WS, Hamburger WW, Katz LN. Coronary arteriosclerosis, coronary thrombosis, and the resulting myocardial changes. An evaluation of their respective clinical pictures including the electrocardiographic records, based on the anatomical findings. Am Heart J 1935; 10: 567–595.Google Scholar
  69. 69.
    Chapman I. Morphogenesis of occluding coronary artery thrombosis. Arch Pathol 1965; 80: 256–261.PubMedGoogle Scholar
  70. 70.
    Constantinides P. Plaque fissures in human coronary thrombosis. J Atheroscler Res 1966; 6: 1–17.Google Scholar
  71. 71.
    Bouch DC, Montgomery GL. Cardiac lesions in fatal cases of recent myocardial ischaemia from a coronary care unit. Br Heart J 1970; 32: 795–803.PubMedGoogle Scholar
  72. 72.
    Ridolfi RL, Hutchins GM. The relationship between coronary artery lesions and myocardial infarcts: ulceration of atherosclerotic plaques precipitating coronary thrombosis. Am Heart J 1977; 93: 468–486.PubMedGoogle Scholar
  73. 73.
    Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/ or sudden death. Circulation 1985; 71: 699–708.PubMedGoogle Scholar
  74. 74.
    Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 1984; 310: 1137–1140.PubMedGoogle Scholar
  75. 75.
    Taeymans Y, Theroux P, Lesperance J, Waters D. Quantitative angiographic morphology of the coronary artery lesions at risk of thrombotic occlusion. Circulation 1992; 85: 78–85.PubMedGoogle Scholar
  76. 76.
    Santamore WP, Yelton Jr BW, Ogilby JD. Dynamics of coronary occlusion in the pathogenesis of myocardial infarction. J Am Coll Cardiol 1991; 18: 1397–405.PubMedGoogle Scholar
  77. 77.
    Liebson PR, Klein LW. Intravascular ultrasound in coronary atherosclerosis: a new approach to clinical assessment. Am Heart J 1992; 123: 1643–1650.PubMedGoogle Scholar
  78. 78.
    Bartorelli AL, Neville RF, Keren G, Potkin BN, Almagor Y, Bonner RF, et al. In vitro and in vivo intravascular ultrasound imaging. Eur Heart J 1992; 13: 102–108.PubMedGoogle Scholar
  79. 79.
    Toussaint J-F, Southern JF, Fuster V, Kantor HL. T2-weighted contrast for NMR characterization of human atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15: 1533–1542.PubMedGoogle Scholar
  80. 80.
    Dangas G, Mehran R, Wallenstein S, Courcoutsakis NA, Kakarala V, Hollywood J, et al. Correlation of angiographic morphology and clinical presentation in unstable angina. J Am Coll Cardiol 1997; 29: 519–525.PubMedGoogle Scholar
  81. 81.
    Bresnahan DR, Davis JL, Holmes DR Jr, Smith HC. Angiographic occurrence and clinical correlates of intraluminal coronary artery thrombus: role of unstable angina. J Am Coll Cardiol 1985; 6: 285–289.PubMedGoogle Scholar
  82. 82.
    Vetrovec GW, Cowley MJ, Overton H, Richardson DW. Intracoronary thrombus in syndromes of unstable myocardial ischemia. Am Heart J 1981; 1202–1208.Google Scholar
  83. 83.
    Zack PM, Ichinger T, Aker UT, Dincer B, Kennedy HL. The occurrence of angiographically detected intracoronary thrombus in patients with unstable angina pectoris. Am Heart J 1984; 108: 1408–1412.PubMedGoogle Scholar
  84. 84.
    Sherman CT, Litvack F, Grundfest W, Lee M, Hickey A, Chaux A, et al. Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 1986; 315: 913–919.PubMedGoogle Scholar
  85. 85.
    Kragel AH, Gertz SD, Roberts WC. Morphologic comparison of frequency and types of acute lesions in the major epicardial coronary arteries in unstable angina pectoris, sudden coronary death and acute myocardial infarction. J Am Coll Cardiol 1991; 18: 801–808.PubMedGoogle Scholar
  86. 86.
    Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973–979.PubMedGoogle Scholar
  87. 87.
    Hatton MWC, Moar SL, Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface. Correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol 1989; 135: 499–508.PubMedGoogle Scholar
  88. 88.
    Hatton MWC, Southward SMR, Ross-Ouellet B, DeReske M, Blajchman MA, Richardson M. An increased uptake of prothrombin, antithrombin, and fibrinogen by the rabbit balloon-deendothelialized aorta surface in vivo is maintained until reendothelialization is complete. Arterioscler Thromb Vasc Biol 1996; 16: 1147–1155.PubMedGoogle Scholar
  89. 89.
    Speidel CM, Eisenberg PR, Ruf W, Edgington TS, Abendschein DR. Tissue factor mediates prolonged procoagulant activity on the luminal surface of ballon-injured aortas in rabbits. Circulation 1995; 92: 3323–3330.PubMedGoogle Scholar
  90. 90.
    Marmur JD, Thiruvikraman SV, Fyfe BS, Guha A, Sharma SK, Ambrose JA, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996; 94: 1226–1232.PubMedGoogle Scholar
  91. 91.
    Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839–2843.PubMedGoogle Scholar
  92. 92.
    Annex BH, Denning SM, Channon KM, Sketch MH Jr, Stack RS, Morrissey JH, et al. Differential expression of tissue factor protein in directional atherectomy specimens from patients with stable and unstable coronary syndromes. Circulation 1995; 91: 619–622.PubMedGoogle Scholar
  93. 93.
    Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594–599.PubMedGoogle Scholar
  94. 94.
    Barry WL, Gimple LW, Humphries JE, Powers ER, McCoy KW, Sanders JM, et al. Arterial thrombin activity after angioplasty in an atherosclerotic rabbit model. Time course and effect of hirudin. Circulation 1996; 94: 88–93.PubMedGoogle Scholar
  95. 95.
    Bar-Shavit R, Eldor A, Vlodaysky I. Binding of thrombin to subendothelial extracellular matrix. Protection and expression of functional properties. J Clin Invest 1989; 84: 1096–1104.PubMedGoogle Scholar
  96. 96.
    Nelken NA, Soifer SJ, O’Keefe J, Vu T-K H, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atheroosclerotic human arteries. J Clin Invest 1992; 90: 1614–1621.PubMedGoogle Scholar
  97. 97.
    Lundgren CH, Sawa H, Sobel BE, Fujii S. Modulation of expression of monocyte/macrophage plasminogen activator activity and its implications for attenuation of vasculopathy. Circulation 1994; 90: 1927–1934.PubMedGoogle Scholar
  98. 98.
    Marczin N, Antonov A, Papapetropoulos A, Munn DH, Virmani R, Kolodgie FD, et al. Monocyte-induced downregulation of nitric oxide synthase in cultured aortic endothelial cells. Arterioscler Thromb Vasc Biol 1996; 16: 1095–1103.PubMedGoogle Scholar
  99. 99.
    Gupta M, Doellgast GJ, Cheng T, Lewis JC. Expression and localization of tissue factor-based procoagulant activity (PCA) in pigeon monocyte-derived macrophages. Thromb and Haemost 1993; 70: 963–969.Google Scholar
  100. 100.
    Zeldis SM, Nemerson Y, Pitlick FA, Lentz TL. Tissue factor (thromboplastin): localization to plasma membranes by peroxidase-conjugated antibodies. Science 1972; 175: 766–768.PubMedGoogle Scholar
  101. 101.
    Tipping PG, Malliaros J, Holdsworth SR. Procoagulant activity expression by macrophages from atheromatous vascular plaques. Atherosclerosis 1989; 79: 237–243.PubMedGoogle Scholar
  102. 102.
    Rickles FR, Levin JA, Hardin JA, Barr CF, Conrad ME. Tissue factor generation by human mononuclear cells: effects of endotoxin and dissociation of tissue factor generation from mitogenic response. J Lab Clin Med 1977; 89: 792–803.PubMedGoogle Scholar
  103. 103.
    Rothberger H, Zimmerman TS, Spiegelberg HL, Vanghan JE. Leukocyte procoagulant activity: enhancement of production in vitro by IgG and antigen antibody complexes. J Clin Invest 1977; 59: 459–466.Google Scholar
  104. 104.
    Muhlfelder TW, Niemitiz J, Krentzer D, Beebe D, Word P, Rosenfield SI. C5 chemotactic fragment leukocyte production of tissue factor activity. J Clin Invest 1979; 63: 147–150.PubMedGoogle Scholar
  105. 105.
    Dean RT, Prydz H. Inflammatory particles stimulate thromboplastin production by human monocytes. Thromb Res 1983; 30: 357–367.PubMedGoogle Scholar
  106. 106.
    Semen GG, Abbate R, Gori AM, Attanasio M, Martini F, Giusti B, et al. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation 1992; 86: 790–797.Google Scholar
  107. 107.
    De Servi S, Mazzone A, Ricevuti G, Mazzucchelli I, Fossati G, Gritti D, et al. Clinical and angiographic correlates of leukocyte activation in unstable angina. J Am Coll Cardiol 1995; 26: 1146–1150.PubMedGoogle Scholar
  108. 108.
    Hynes RO. Integrins: a family of cell surface receptors. Cell 1987; 48: 549–554.PubMedGoogle Scholar
  109. 109.
    Plow EF, Ginsberg MH. Cellular adhesion: GPIIb/IIIa as a prototypic adhesion receptor. Prog Hemost Thromb 1989; 9: 117–156.PubMedGoogle Scholar
  110. 110.
    Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11–25.PubMedGoogle Scholar
  111. 111.
    Sanches-Madrid F, Nagy JA, Robbins E, Simon P, Springer TA. A human leukocyte differentiation antigen family with distinct a subunits and common f3 subunit. J Exp Med 1983; 158: 1785–1803.Google Scholar
  112. 112.
    Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990; 4: 2868–2880.PubMedGoogle Scholar
  113. 113.
    Bevilacqua MP, Nelson RM. Selectins. J Clin Invest 1993; 91: 379–387.PubMedGoogle Scholar
  114. 114.
    Kasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 1992; 259: 964–969.Google Scholar
  115. 115.
    Israels SJ, Gerrard JM, Jacques YV, McNicol A, Cham B, Nishibori M, et al. Platelet dense granule membranes contain both granulophisin and P-selectin (GMP-140). Blood 1992; 80: 143–152.PubMedGoogle Scholar
  116. 116.
    Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990; 75: 550–554.PubMedGoogle Scholar
  117. 117.
    Picker LJ. Mechanisms of lymphocyte homing. Curr Poin Immunol 1992; 4: 277–286.Google Scholar
  118. 118.
    Spertini O, Luscinskas FW, Kansas GS, Munro JM, Griffin JD, Gimbrone MA Jr, et al. Leukocyte adhesion molecule-1 (LAM-1, L-selectin) interacts with an inducible endothelial cell ligand to support leukocyte adhesion. J Immunol 1991; 147: 2565–2573.PubMedGoogle Scholar
  119. 119.
    Kishimoto TK, Jutila MA, Berg EL, Butcher EC. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 1989; 245: 1238–1241.PubMedGoogle Scholar
  120. 120.
    Dustin ML, Stauton DE, Springer TA. Supergene families meet in the immune system. Immunol Today 1988; 9: 213–215.PubMedGoogle Scholar
  121. 121.
    Liuzzo G, Biasucci LM, Gallimore JR, Grillo GL, Rebuzzi AG, Pepys MB, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417–424.PubMedGoogle Scholar
  122. 122.
    Becker R, Cannon C, Bovill E, Tracy R, Thompson B, Knatterud G, et al. Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB Trial). Am J Cardiol 1996; 78: 142–147.PubMedGoogle Scholar
  123. 123.
    Lefvert A, Hamsten A, Holm G. Association between circulating immune complexes, complement C4 null alleles, and myocardial infarction before age 45 years. Arterioscler Thromb Vasc Biol 1995; 15: 665–668.PubMedGoogle Scholar
  124. 124.
    Neumann FJ, Ott I, Gawaz M, Richardt G, Hozapfel H, Jochum M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995; 92: 748–755.PubMedGoogle Scholar
  125. 125.
    Furman M, Becker R, Yarzebski J, Savegeau J, Gore J, Goldberg R. Effect of elevated leukocyte count on in-hospital mortality following acute myocardial infarction. Am J Cardiol 1996; 78: 945–948.PubMedGoogle Scholar
  126. 126.
    Van Mourik JA, Lawrence PA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelail cells. J Biol Chem 1984; 259: 14914–14921.PubMedGoogle Scholar
  127. 127.
    Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, et al. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673–1680.PubMedGoogle Scholar
  128. 128.
    Ny T, Sawdey M, Lawrence D, Millan JL, Loskutoff DJ. Cloning and sequence of cDNA coding for the human (3-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776–6780.PubMedGoogle Scholar
  129. 129.
    Declerck PJ, DeMol M, Alessi MC, Baudner S, Paques EP, Preissmer KT, et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. J Biol Chem 1988; 263: 15454–15461.PubMedGoogle Scholar
  130. 130.
    Vaughan DE, Declerck PJ, Reilly TM, Park K, Collen D, Fasman GD. Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1(rPAI-1). Biochim Biophys Acta 1993; 1202: 221–229.PubMedGoogle Scholar
  131. 131.
    Lambers JW, Cammenga M, Konig BW, Mertens K, Pannekoek H, van Mourik JA. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J Biol Chem 1987; 262: 17492–17496.PubMedGoogle Scholar
  132. 132.
    Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381–387.PubMedGoogle Scholar
  133. 133.
    Sprengers ED, Princen HM, Kooistra T, van Hinsbergh VW. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985; 105: 751–758PubMedGoogle Scholar
  134. 134.
    Knudsen BS, Harpel PC, Nachman RL. Plasminogen activator inhibitor is associated with the extra-cellular matrix of cultured bovine smooth muscle cells. J Clin Invest 1987; 80: 1082–1089.PubMedGoogle Scholar
  135. 135.
    Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: Development of a radio-immunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645–1653.PubMedGoogle Scholar
  136. 136.
    Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989; 74: 222–228.PubMedGoogle Scholar
  137. 137.
    Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998–7002.PubMedGoogle Scholar
  138. 138.
    Hamsten A, Wiman B, Faire UD, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557–1563.PubMedGoogle Scholar
  139. 139.
    Hamsten A, de Faire U, Walldius G, Szamosi A, Landou C, Blomback M, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3–9.PubMedGoogle Scholar
  140. 140.
    Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989; 13: 305–314.PubMedGoogle Scholar
  141. 141.
    Katz AM. Angiotensin-II: hemodynamic regulator or growth factor? J Mol Cell Cardiol 1990; 22: 739–747.PubMedGoogle Scholar
  142. 142.
    Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin angiotensin system and firinolytic function. Circulation 1993; 87: 1969–1973.PubMedGoogle Scholar
  143. 143.
    Olson JA Jr, Shiverick KT, Ogilvie S, Buhi WC, Raizade MK. Angiotensin II induces secretion of plasminogen activator inhibitor-I and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes. Neurobiology 1991; 88: 1928–1932.Google Scholar
  144. 144.
    Vaughan DE, Rouleau J-L, Ridker PM, Arnold JMO, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. Circulation 1997; 96: 442–447.PubMedGoogle Scholar
  145. 145.
    Brozovic M, Stirling Y, Harricks C. Factor VII in an industrial population. Br J Haematol 1974; 28: 381–391.PubMedGoogle Scholar
  146. 146.
    Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VII and von Willebrand factor with age, race, sex and risk factors for atherosclerosis. Thromb Haemost 1993; 3: 380–385.Google Scholar
  147. 147.
    Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. JAMA 1987; 258: 1183–1186.PubMedGoogle Scholar
  148. 148.
    Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long term mortality in patients with coronary artery disease: a 7-year follow up. Circulation 1993; 88: 2030–2034.PubMedGoogle Scholar
  149. 149.
    Keys A. Coronary heart disease in seven countries. Circulation 1970; 41: 1–211.Google Scholar
  150. 150.
    Walker ID, Davidson JF, Hutton I. Disordered fibrinolytic potential in coronary heart disease. Thromb Res 1977; 15: 114A.Google Scholar
  151. 151.
    Tremoll E, Maderna P, Calil S, et al. Increased platelet sensitivity and thromboxane B2 formation in type-II hyperlipoproteinemic patients. Eur J Clin Invest 1984; 14: 329–333.Google Scholar
  152. 152.
    Wilkes HC, Meade TW, Barzegar S, Foley AJ, Hughes LO, Bauer KA, et al. Gemfibrozil reduces plasma prothrombin fragment F1+2 concentration, a marker of coagulability, in patients with coronary heart disease. Thromb Haemost 1992; 67: 503–506.PubMedGoogle Scholar
  153. 153.
    Eisenberg PR, Sherman LA, Schectman K, Perez J, Sobel BE, Jaffe AS. Fibrionopeptide A: a marker of acute coronary thrombosis. Circulation 1985; 71: 912–918.PubMedGoogle Scholar
  154. 154.
    Becker RC, Bovill E, Corrao JM, Ball SP, Ault K, Mann DG, et al. Platelet activity persists among patients with unstable angina and non-Q wave myocardial infarction. J Thromb Thrombolysis 1994; 1: 95–100.PubMedGoogle Scholar
  155. 155.
    Becker RC, Tracy RP, Bovill EG, Corrao JM, Baker S, Ball SP, et al. Surface 12-lead electrocardiographic findings and plasma markers of thrombin activity and generation in patients with myocardial ischemia at rest. J Thromb Thrombolysis 1994; 1: 101–107.PubMedGoogle Scholar
  156. 156.
    Forrester J. Intimal disruption and coronary thrombosis: its role in the pathogenesis of human coronary disease. Am J Cardiol 1991; 68: 69B - 77B.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1999

Authors and Affiliations

  • Richard C. Becker

There are no affiliations available

Personalised recommendations